GLS — Glenmark Life Sciences Balance Sheet
0.000.00%
Last trade - 00:00
- IN₹98.34bn
- IN₹94.10bn
- IN₹21.61bn
- 94
- 43
- 82
- 89
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 20.6 | 100 | 1,156 | 5,122 | 2,838 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 5,176 | 7,073 | 7,268 | 7,152 | 9,189 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 9,307 | 11,601 | 13,990 | 17,646 | 18,503 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 5,303 | 5,498 | 5,790 | 6,763 | 8,242 |
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 14,754 | 17,256 | 19,971 | 24,710 | 27,021 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 13,804 | 13,075 | 12,214 | 3,840 | 5,044 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Funded Status | |||||
Total Liabilities | 13,873 | 13,239 | 12,443 | 4,167 | 5,639 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 881 | 4,017 | 7,527 | 20,543 | 21,382 |
Total Liabilities & Shareholders' Equity | 14,754 | 17,256 | 19,971 | 24,710 | 27,021 |
Total Common Shares Outstanding |